• Publications
  • Influence
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.
Authors/Task Force Members, Kim Fox, Chairperson*, Maria Angeles Alonso Garcia, Madrid (Spain), Diego Ardissino, Parma (Italy), Pawel Buszman, Katowice (Poland), Paolo G. Camici, London (UK), FilippoExpand
  • 325
  • 37
  • PDF
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.
BACKGROUND Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents mayExpand
  • 581
  • 30
  • PDF
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
BACKGROUND New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis. However, it is unclear whether there are differences in efficacy andExpand
  • 626
  • 27
  • PDF
Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization.
OBJECTIVES The purpose of this study was to compare the early and late results of percutaneous and surgical revascularization of left main coronary artery stenosis. BACKGROUND Unprotected left mainExpand
  • 370
  • 15
  • PDF
Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial.
OBJECTIVES We aimed to assess the predictive value of the SYNTAX score (SXscore) for major adverse cardiac events in the all-comers population of the LEADERS (Limus Eluted from A Durable versusExpand
  • 193
  • 11
  • PDF
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
BACKGROUND A novel stent platform eluting biolimus, a sirolimus analogue, from a biodegradable polymer showed promising results in preliminary studies. We compared the safety and efficacy of aExpand
  • 418
  • 8
Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry.
OBJECTIVES The aim of the study was to evaluate early and late outcomes after percutaneous coronary intervention (PCI) of unprotected left main coronary artery disease (ULMCA) and to compareExpand
  • 127
  • 8
  • PDF
[Guidelines on the management of stable angina pectoris: executive summary].
Authors/Task Force Members, Kim Fox, Chairperson*, Maria Angeles Alonso Garcia, Madrid (Spain), Diego Ardissino, Parma (Italy), Pawel Buszman, Katowice (Poland), Paolo G. Camici, London (UK), FilippoExpand
  • 696
  • 6
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
Abstract Aims To investigate if recent technical and procedural developments in percutaneous coronary intervention (PCI) significantly influence outcomes in appropriately selected patients withExpand
  • 137
  • 5
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in
BACKGROUND Inhibition of the P2Y12 ADP-receptor with oral antiplatelet agents given to patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarctionExpand
  • 97
  • 4
...
1
2
3
4
5
...